Hints and tips:
Related Special Reports
...While acknowledging that AstraZeneca has “a global reach, is in a high-paying sector, with a particularly well-regarded CEO at the helm,” ISS said that it remained concern by “the scale of the increase”....
...“There is a compensation issue at AstraZeneca,” Jain, a top-20 shareholder, told the Financial Times....
...In recommending that investors oppose the plans, ISS said it acknowledged that AstraZeneca, the UK’s second-largest public company by market value, has “a global reach, is in a high-paying sector, with a...
...Fruergaard Jørgensen said that a tablet product from the acquisition last year of a Canadian biotech, Inversago, could be a scalable weight-loss pill and alternative to the popular GLP-1-based drugs....
...The bill labels Shanghai-based WuXi AppTec “a biotechnology company of concern”, which is described as any entity posing a risk to the US by engaging in joint research with a foreign adversary’s military...
...drug breaks down into a carcinogen....
...It recently sold a large site in California to contract manufacturer Lonza for $1.2bn....
...These price concessions increased from 20 instances per month before 2016 to a peak of 199 per month in late 2022....
...As Emblaveo is a combination of two existing antibiotic treatments, aztreonam and avibactam, it would not qualify as a “priority” drug eligible for a voucher....
...or offer solutions for patients at a later stage.”...
...“This is a legal battle, but it’s a PR battle in many ways,” said Ana Santos Rutschman, a law professor at Villanova University in the US state of Pennsylvania, who is an expert in life sciences intellectual...
...A spokesperson for China’s Ministry of Foreign Affairs said: “China is a country ruled by law. All Chinese law enforcement and judicial activities are carried out based on facts and the law....
...“This is not a problem just for the heroin users. This is a problem for a wider population of people who use drugs, who might not think that they’re at risk of xylazine harm,” she added....
...“The whole system has a just-in-time principle and any rupture in that causes a downstream shortage,” says Rob Moss, a hospital pharmacy consultant in Utrecht, the Netherlands....
...AstraZeneca shareholders approved a potential £1.8mn pay rise for chief executive Pascal Soriot, despite a significant investor revolt against a pay increase advisers had called “excessive”....
...The success for Imfinzi, which is approved for other cancers, comes after a setback in a trial in November to expand its use for another terminal lung cancer....
...The company will increase its footprint at a Cambridge biomedical site and build a vaccine manufacturing site in Speke in Liverpool....
...Shareholders will vote later today on a plan to raise Soriot’s pay by £1.8mn to a maximum of £18.7mn in 2024....
...Novo Nordisk has struck a €1bn deal for a German biotech developing ribonucleic acid-based therapies to treat heart disease, as the Danish group invests the windfall from its best-selling diabetes and weight...
...The funds have been awarded by the British Business Bank, a state-owned lender.The money is part of the government’s ambition to encourage pension schemes to invest more in unlisted UK companies....
...Patients require a single treatment....
...The results from the research, which involved 156 people, were a “major breakthrough”, said Olivier Rascol, a Toulouse University Hospital professor and a co-author of the research with Prof Wassilios Meissner...
...Canadian biotech Fusion is a specialist in radioconjugates, a drug type that involves delivering a radioactive isotope directly to cancer cells through precise targeting, reducing the damaging side effects...
...Novo Nordisk has struck a €1bn deal for Cardior Pharmaceuticals, a German biotech company developing RNA-based therapies to treat heart disease, as it seeks to build expertise in diseases beyond diabetes...
International Edition